This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SAC Dumps Huge Dendreon Stake

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

BOSTON ( TheStreet) -- Billionaire hedge fund manager Steven Cohen was the largest and most noteworthy seller of troubled biotech firm Dendreon (DNDN) during the third quarter, according to new regulatory filings Monday.

Cohen's SAC Capital Advisors dumped 8.36 million shares of Dendreon during the third quarter. Dendreon shares plummeted in early August after the company reported poor sales and offered a bleak financial outlook for its Provenge prostate cancer therapy.

Dendreon shares, at Monday's close of $7.27, are down 80% since early August.

More likely than not, SAC took a huge financial hit due to Dendreon's blow up, although the firm's exact losses in the position are not disclosed in the 13F filed with the Securities and Exchange Commission Monday night.

Dendreon was the largest single stock holding by position value in SAC's portfolio --$351 million. By contrast, Cohen's hedge fund owned just 241,700 shares of Dendreon with a value of $2.17 million at the end of the September quarter.

Other big sellers of Dendreon in the third quarter included George Soros' Soros Fund Management, which shed 2.4 million shares; and Brookside Capital Management, which dumped 1.2 million shares, according to regulatory filings.

While some Wall Street investors were tending to their Dendreon-induced wounds, still others were taking advantage of the stock's slide to buy new positions.

Baker Brothers Advisors gobbled up 2.6 million shares during the September quarter. Camber Capital Management also initiated a new Dendreon position with a 2 million-share purchase.

Millennium Management bought nearly 2.6 million shares in Dendreon to dramatically increase what was previously a small position in the cancer therapy company. Likewise, Orbimed Advisors acquired 803,000 shares.

Whether these funds do any better with Dendreon than SAC is unclear following another troubling earnings report from the company in early November.

Hedge funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F filed SEC within 45 days of the end of a quarter. Funds aren't required to report short positions betting on declines.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs